Riverhead Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Riverhead Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$12K	Hold	127	–	–	﹤0.01%	1484
2019 Q2	$15K	Sell	127 -10	-7%	-$1.2K	﹤0.01%	1502
2019 Q1	$16K	Sell	137 -88	-39%	-$7.71K	﹤0.01%	1476
2018 Q4	$14K	Sell	225 -299	-57%	-$18.8K	﹤0.01%	1477
2018 Q3	$37K	Sell	524 -35	-6%	-$2.41K	﹤0.01%	1511
2018 Q2	$37K	Buy	559 +419	+299%	+$27.6K	﹤0.01%	1491
2018 Q1	$9K	Buy	+140	New	+$7.87K	﹤0.01%	1525

Other funds holding ASND

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Riverhead Capital Management's ASND Position: Q3 2019 in Review

Riverhead Capital Management held its Ascendis Pharma A/S (ASND) position steady in Q3 2019 at 127 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #1484.

Riverhead Capital Management first reported a position in ASND in Q1 2018 and has held it in 7 quarters since. The position peaked at $37K in Q3 2018. 129 funds tracked by Wall St. Rank hold ASND as of Q3 2019.

Riverhead Capital Management held 127 shares of Ascendis Pharma A/S worth $12K as of Q3 2019.
Riverhead Capital Management left its Ascendis Pharma A/S share count unchanged in Q3 2019.
Ascendis Pharma A/S made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1484 holding.
Riverhead Capital Management first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 7 quarters since.
Riverhead Capital Management's Ascendis Pharma A/S position peaked at $37K in Q3 2018.
129 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.